🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

BMO cuts Entegris stock target price on softer outlook, maintains Outperform rating

EditorTanya Mishra
Published 08/01/2024, 09:35 AM
ENTG
-

On Thursday, BMO Capital Markets adjusted its stance on Entegris Inc (NASDAQ: NASDAQ:ENTG), a supplier to the semiconductor industry, by lowering its price target to $145 from $160 while maintaining an Outperform rating on the stock.

The move comes after Entegris reported second-quarter earnings that met expectations but provided a third-quarter outlook that was less robust than anticipated, along with a slight reduction in its full-year 2024 guidance.

The analyst from BMO Capital expressed that the market had high expectations for Entegris, noting that it is currently a period when electronics and semiconductor-exposed companies in their coverage are frequently reporting earnings above expectations and raising guidance.

However, Entegris' in-line second-quarter earnings were overshadowed by the softer third-quarter outlook and the mild cut in the full-year 2024 forecast.

Despite the near-term earnings hiccup, BMO Capital believes Entegris' long-term growth narrative remains solid and unchanged. The firm has adjusted its estimates and target price to align with the short-term trends affecting the company.

The analyst underscored the point by stating, "In our view, despite the air pocket in ENTG's short-term earnings ramp, its long-term growth story remains robust and intact."

Entegris has experienced a significant stock price correction, especially when compared to the broader market. BMO Capital views this as an opportune moment for investors, suggesting that the current lower stock price offers an attractive entry point into the stock.

InvestingPro Insights

Entegris Inc (NASDAQ: ENTG) has been under the microscope after its recent earnings report and guidance update, which has led to a revised price target from BMO Capital Markets. To provide additional context to investors, InvestingPro data and tips offer a deeper dive into the company's financial health and market performance.

InvestingPro data highlights that Entegris is currently trading at a high earnings multiple, with a P/E ratio of 97.68, and an adjusted P/E ratio for the last twelve months as of Q2 2024 at 76.4. This valuation suggests that investors are paying a premium for the company's earnings compared to the market average. Additionally, the company has a Price/Book ratio of 5.09 for the same period, indicating that the stock might be valued richly in relation to its net assets.

Despite a revenue decline of 12.73% in the last twelve months as of Q2 2024, Entegris maintains a strong gross profit margin of 43.6%. This indicates that the company has been effective in managing its cost of goods sold and maintaining profitability on its products.

From the perspective of InvestingPro Tips, Entegris is recognized for its high shareholder yield, which is a positive sign for investors seeking returns. Moreover, while analysts have revised their earnings estimates downwards for the upcoming period, Entegris is still expected to be profitable this year, with net income projected to grow. This could be a signal that the company's fundamentals remain strong despite short-term headwinds.

For those seeking additional insights, InvestingPro offers a total of 11 tips for Entegris, which can be explored further at https://www.investing.com/pro/ENTG. These tips may help investors understand the nuances of the company's performance and potential investment opportunities.

Given the mixed signals from both the latest earnings report and InvestingPro data, investors might consider the current market valuation and the company's profitability prospects when assessing the investment potential of Entegris. BMO Capital's positive long-term outlook aligns with some of the strengths highlighted by InvestingPro, suggesting that while near-term challenges exist, the company's long-term growth narrative could still be compelling for patient investors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.